Actionable news
0
All posts from Actionable news
Actionable news in VRX: VALEANT PHARMACEUTICALS INTERNATIONAL,

22 Stocks Moving In Tuesday's Pre-Market Session


Gainers

  • Osiris Therapeutics, Inc. OSIR shares rose 15 percent to $4.82 in pre-market trading. Osiris Therapeutics expects that 2014 will restate revenue to $46 million-$50 million. The company projects 2015 revenue of $85 million to $90 million and FY16 revenue of$100 million to $110 million.
  • Pernix Therapeutics Holdings Inc PTX shares rose 8.1 percent to $4.16 in pre-market trading. Pernix Therapeutics reported the appointment of Graham G. Miao, Ph.D. and Dennis H. Langer, M.D., J.D. to its board.
  • Priceline Group Inc PCLN rose 4.8 percent to $1,551.00 in pre-market trading after the company reported stronger-than-expected earnings for its third quarter. The firm’s interim CEO, Brett Keller, has been named Chief Executive Officer of Priceline.com, and will respond to the company’s Interim CEO and Chairman of the Board Jeffery H. Boyd.

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Losers

  • Hertz Global Holdings, Inc HTZ shares fell 36.3 percent to $22.76 in pre-market trading after the company reported weaker-than-expected results for the third quarter and provided downbeat forecast for the full year.
  • Kindred Healthcare, Inc. KND shares fell 25.1 percent to $6.55 in pre-market trading after the company reported wider Q3 loss and announced plans to exit the skilled nursing facility business.
  • CVS Health Corp CVS shares fell 15 percent to $70.96 in pre-market trading. CVS delivered better than expected EPS for the third quarter though revenue missed. However, the company offered downbeat guidance for the fourth quarter and next year.
  • Valeant Pharmaceuticals Intl Inc VRX fell 9.3 percent to $17.36 in pre-market trading as the company reported weaker-than-expected earnings for its third quarter and lowered its full year fiscal 2016 guidance.

© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.